TABLE 2.
Baseline characteristics of 90 clinically evaluable patients enrolled in the FAST II trial with an available pretreatment S. aureus isolate from a site of skin and soft tissue infection
| Parameter | No. of patients (% of total)a |
|---|---|
| Patient demographics | |
| Age | 42.1 ± 10.9b |
| Male | 52 (58) |
| White race | 64 (71) |
| Predisposing conditions | |
| Prior surgery | 32 (36) |
| Diabetes | 16 (18) |
| Trauma | 15 (17) |
| Source of skin infection | |
| Major abscess | 66 (73) |
| Infected burn | 0 (0) |
| Deep/extensive cellulitis | 15 (17) |
| Infected ulcer | 2 (2) |
| Wound infection | 7 (8) |
| Prior antimicrobial therapy | 54 (60) |
| Infection with MRSA | 44 (49) |
| Randomized antibiotic treatment assignment | |
| Telavancin | 50 (56) |
| Standard therapy by investigator's choice | 40 (44) |
| Vancomycin | 38 (95) |
| Nafcillin, oxacillin, or cloxacillin | 2 (5) |
| Geography | |
| United States (11 centers) | 56 (62) |
| South Africa (7 centers) | 34 (38) |
a
Percentages are based on a total patient population of 90.
b
Mean (yr) ± standard deviation.